Amgen Says Dazodalibep Meets Primary Endpoint In Phase 3 Sjögren's Disease Trial
AMGN•Phase 3 trial results
Sept. 22 (Reuters) - Amgen Inc AMGN.O:
- Amgen: Phase 3 OASIZ 303 study of dazodalibep in moderate-to-severe symptomatic Sjögren’s disease expected to complete in Q4 2026
- Amgen: Dazodalibep meets primary endpoint in Phase 3 Sjögren's disease trial
- Amgen: Dazodalibep showed statistically significant & clinically meaningful improvement in systemic disease activity
